Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze

Neuroscience Letters

Volumn 475, Issue 3, 2010, Pages 165-168

  Huang, Peng ^a   Liu Chen, Lee Yuan ^a   Kirby, Lynn G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abstinence; Anxiety; Cannabinoid; Elevated plus maze; Mice; Rimonabant; SR141716; THC; Withdrawal

Indexed keywords

DRONABINOL; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; EMOTIONS; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; PIPERIDINES; PSYCHOTROPIC DRUGS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 77952546606     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.03.071     Document Type: Article

References (20)

1. Arevalo C., de Miguel R., Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 2001, 70:123-131.
2. Bonn-Miller M.O., Moos R.H. Marijuana discontinuation, anxiety symptoms, and relapse to marijuana. Addict. Behav. 2009, 34:782-785.
3. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 1996, 277:586-594.
4. Cook S.A., Lowe J.A., Martin B.R. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1998, 285:1150-1156.
5. Cooper Z.D., Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict. Biol. 2008, 13:188-195.
6. Degroot A., Nomikos G.G. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur. J. Neurosci. 2004, 20:1059-1064.
7. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 2001, 125:151-157.
8. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 2005, 57:261-267.
9. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 2002, 16:1395-1398.
10. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 1996, 54:21-30.
11. Huang P., Liu-Chen L.Y., Unterwald E.M., Cowan A. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neurosci. Lett. 2009, 465:66-70.
12. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., Maldonado R. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br. J. Pharmacol. 1998, 125:1567-1577.
13. Lichtman A.H., Martin B.R. Marijuana withdrawal syndrome in the animal model. J. Clin. Pharmacol. 2002, 42:20S-27S.
14. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 2001, 298:1007-1014.
15. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol. Ther. 2002, 95:153-164.
16. Navarro M., Hernandez E., Munoz R.M., del A.I., Villanua M.A., Carrera M.R., Rodriguez d.F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997, 8:491-496.
17. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 2006, 318:304-311.
18. Rodgers R.J., Haller J., Halasz J., Mikics E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 2003, 17:1279-1286.
19. Rodriguez d.F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
20. Wilson D.M., Varvel S.A., Harloe J.P., Martin B.R., Lichtman A.H. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol. Biochem. Behav. 2006, 85:105-113.